{"schema_version":"secwatch.filing_event.v1","accession":"0001420720-26-000006","form_type":"8-K","ticker":"IBIO","cik":"0001420720","company_name":"iBio, Inc.","filed_at":"2026-03-09T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.043827+00:00","generated_at":"2026-05-15T17:35:52.512817+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"iBio reports IBIO-610 reduces visceral fat 6.7%, total fat 5.2% in obese NHPs; expands into cardiopulmonary","bullets":["Preclinical study: IBIO-610 reduced visceral fat by 6.7% and total fat mass by 5.2% after two doses every 8 weeks.","Extended half-life of 33.2 days in NHPs; projected human half-life up to 100 days suggesting twice-yearly dosing.","Company announces strategic expansion into cardiopulmonary space, targeting PH-HFpEF with myostatin x Activin A bispecific.","Data consistent with other Activin E pathway approaches; full dataset to be presented at scientific conferences in 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001420720-26-000006","json":"https://secwatch.observer/filing/0001420720-26-000006.json","markdown":"https://secwatch.observer/filing/0001420720-26-000006.md","text":"https://secwatch.observer/filing/0001420720-26-000006.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1420720/000142072026000006/0001420720-26-000006-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1420720/000142072026000006/ibio-20260309x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T17:35:52.512817+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}